Insiders who reported open-market trades in the last 12 months at the companies Matthew T. Wiley files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Robert Barrow - $3.98M in DFTX purchases and sales in the last 12 months
Mark Sullivan - $1.45M in DFTX purchases and sales in the last 12 months
Daniel Karlin - $1.07M in DFTX purchases and sales in the last 12 months
Brandi Roberts - $259K in DFTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Matthew T. Wiley is a corporate insider, tracked as Chief Commercial Officer of Definium Therapeutics, Inc. (DFTX). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Matthew T. Wiley submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Matthew T. Wiley been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($246K) across all tracked filings.
Matthew T. Wiley is Chief Commercial Officer of Definium Therapeutics, Inc. (DFTX). 7 SEC Form 4 filings on record going back to 2024, most recently on 30 September 2026. Most recent open-market trade: sold $113K of DFTX on 30 September 2026. Lifetime open-market sales: $246K.
Recent transactions
8
The latest 8 SEC Form 4 transactions reported by Matthew T. Wiley.
InsiderAlpha's records for Matthew T. Wiley go back to 2024: 7 primary Form 4 filings, an average of 2.3 per year. 4 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
